KR101688018B1 - Composition for Prevention or Treatment of Prostatic Diseases Comprising Celtis Choseniana Extract - Google Patents
Composition for Prevention or Treatment of Prostatic Diseases Comprising Celtis Choseniana Extract Download PDFInfo
- Publication number
- KR101688018B1 KR101688018B1 KR1020150142201A KR20150142201A KR101688018B1 KR 101688018 B1 KR101688018 B1 KR 101688018B1 KR 1020150142201 A KR1020150142201 A KR 1020150142201A KR 20150142201 A KR20150142201 A KR 20150142201A KR 101688018 B1 KR101688018 B1 KR 101688018B1
- Authority
- KR
- South Korea
- Prior art keywords
- prostate
- extract
- composition
- treatment
- diseases
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 230000002265 prevention Effects 0.000 title claims description 8
- 241000874365 Celtis choseniana Species 0.000 title abstract description 3
- 208000025844 Prostatic disease Diseases 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 208000024891 symptom Diseases 0.000 claims description 12
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 11
- 210000002307 prostate Anatomy 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 7
- 244000215068 Acacia senegal Species 0.000 claims description 6
- 229920000084 Gum arabic Polymers 0.000 claims description 6
- 235000010489 acacia gum Nutrition 0.000 claims description 6
- 239000000205 acacia gum Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 206010020880 Hypertrophy Diseases 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 235000020710 ginseng extract Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 7
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 abstract description 4
- 230000000116 mitigating effect Effects 0.000 abstract 2
- 230000007774 longterm Effects 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 17
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 17
- 208000017497 prostate disease Diseases 0.000 description 16
- 238000000605 extraction Methods 0.000 description 15
- 102100032187 Androgen receptor Human genes 0.000 description 14
- 108010080146 androgen receptors Proteins 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 206010060862 Prostate cancer Diseases 0.000 description 8
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 201000007094 prostatitis Diseases 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 4
- 229960003604 testosterone Drugs 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 3
- 229960004039 finasteride Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 201000004240 prostatic hypertrophy Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000218220 Ulmaceae Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000004566 building material Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000028659 discharge Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011472 radical prostatectomy Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Abstract
Description
The present invention relates to a composition which does not cause adverse side effects or drug resistance of the conventional therapeutic agent, is low in toxicity and can be administered for a long time, and is excellent in prevention and treatment / symptom improvement of prostate diseases.
The prostate gland consists of the glandular tissue and fibrotic tissue, which acts as a secretory gland to secrete and secrete semen. The prostate fluid made from the prostate gland is made in the testis and supplies nutrients to the sperm that has been moved. By keeping the spermatozoa in a liquid state so that the sperm does not get squeezed, it helps the sperm to vigorously exercise. Typical prostate-related diseases include hyperplasia of the prostate, prostate cancer, and prostatitis.
Benign prostatic hyperplasia (BPH) is one of the most common diseases in men and accounts for 50% of men over 50 years old and more than 80% of men over 80 years old. do. The number of patients with hypertrophic prostatitis in Korea has increased from 83% in 2006 to 842,000 in 2011, which is rapidly increasing.
Generally, the size of an adult prostate is about 20 grams, but when the prostate becomes as large as 40 to 400 grams in an abnormal size, it may cause urinary frequency, nighttime urination, strong urge, sudden urination When you feel urine, you can not stand the urine, you can not stand the urinary bladder storage symptoms and urine when you see the urine to urge the urine to stop the flow of urine is cut off urine, urine, urinary symptoms such as the need to give the symptoms of bladder discharge symptoms . Patients with prostatic hypertrophy do not require surgical treatment without urinary tract obstruction or other complications, but about 50% of them need treatment until the age of 80 years. In addition, some of the patients with prostatic hypertrophy are associated with prostate cancer, and although they are not fatal diseases themselves, they are becoming important medical problems of the current society, which is entering into an aging society because it lowers the quality of life.
The treatment of benign prostatic hyperplasia was performed almost at the beginning, but it has been rapidly changing from the late 80s to the drug administration method. However, the drugs used in the treatment of the prostatic hyperplasia of the present invention have many side effects, and their efficacy is limited. Therefore, it is necessary to develop new therapeutic agents which do not cause side effects or drug resistance and have excellent therapeutic effect.
Prostate cancer is the most common cancer among men in the western world, and its incidence is increasing rapidly in Korea. Treatment of prostate cancer differs depending on the progression of the disease. In the case of local cancers, treatment is done for the purpose of radical treatment, but in case of metastatic cancer, systemic treatment is performed. For the treatment of focal prostate cancer, we can choose atmospheric therapy, radical prostatectomy, radiotherapy considering patient's age, health condition, sexual function, tumor stage and differentiation, patient's preference. Metastatic prostate cancer can be treated with hormone therapy or chemotherapy.
Prostatitis is a disease that causes inflammation of the prostate gland. About 50% of men experience symptoms once in their lifetime. In the urinary tract infection, bacteria are most likely to be directly infected through the urethra. In addition, they may be caused by excretion of the prostate fluid, urinary flow into the prostate, or transmission of inflammation such as hemorrhoids or colitis.
Since prostate diseases such as prostate cancer, hyperplasia of the prostate, and prostatitis are associated with the male hormone, androgen, an anti-androgen drug that inhibits the expression of the androgen receptor can be used to treat and prevent the disease and alleviate the symptoms . Or a prostate-specific antigen inhibitor that inhibits the expression of a prostate-specific antigen is also effective for the prevention and treatment / symptom improvement of the prostate disease affected by the prostate-specific antigen.
delete
On the other hand, the black cabbage is a deciduous broad-leaved arboreous tree belonging to the elm family, and its scientific name is Celtis Choseniana. Fruits are harvested in autumn and reproduced. Wood is hard, and it is widely used for building materials, furniture materials, sports fields, cutting boards and mortar. It is known that gum japonicum stem is effective for skin diseases such as wound healing, impetigo, and urticaria, and can be used as a cosmetic composition. Recently, it has been known that it is effective for diseases other than skin diseases such as cervical spondylosis and lung abundance, but the effect on prostate diseases has not been reported.
Disclosure of Invention Technical Problem [8] Accordingly, the present invention has been made to solve the above problems occurring in the prior art, and it is an object of the present invention to provide a novel composition effective for prevention and treatment / symptom improvement of prostate disease.
It is another object of the present invention to provide a composition for prevention and treatment / symptom improvement of prostate disease which is free of toxicity and secured to the human body and can be safely used without side effects or drug resistance.
In order to accomplish the above object, the present invention relates to a pharmaceutical composition for preventing and treating prostate diseases, which comprises gum arabic extract as an active ingredient.
In the present invention, the expression of the androgen receptor (AR) and the prostate-specific antigen (PSA) using LNCap cells, which are commonly used as an experimental model of prostate disease, effectively inhibits the expression of PSA and AR, Of the total number of patients. In particular, the prostate disease may be prostate cancer, hypertrophy of the prostate, or prostatitis.
The gum lucidum extract may be prepared by cultivating leaf, stem, bark, or fruit of ginseng, or extracting at 10 to 100 ° C using one or more of C1-C4 lower alcohol and water. If the extraction temperature is too low, the extraction efficiency is lowered. If the extraction temperature is too high, the activity of the active substance may be lowered. Therefore, it is more preferable to conduct the extraction at 30 to 80 ° C. The extraction may be carried out by simply immersing in a solvent, but extraction may be carried out using ultrasonic waves or heating and stirring so as to increase the extraction efficiency within a short period of time as in the following examples. In order to make the extraction more efficient, the ginseng samples can also be extracted by crushing or grinding into small pieces. The amount of the solvent during the extraction may be 2 to 50 times the volume of the gill kelp. Since the extraction efficiency increases with an increase in the amount of solvent used, it is not a problem to use more than 50 times of the solvent. However, considering the efficiency of the process and economical efficiency, the amount of the solvent is preferably 50 times or less. It is also desirable to increase the extraction times in order to increase the extraction efficiency while using the same amount of solvent.
In order to use the composition of the present invention as a medicament for prevention and treatment, it may be mixed with a carrier or a pharmaceutically acceptable carrier, a forming agent, a diluent or the like by a known method in the pharmaceutical field to prepare tablets, capsules, The pharmaceutical composition may be formulated into oral preparations such as troches, liquids, and suspensions, or parenteral administration preparations such as injectable preparations and wettable powders, and used as a treatment and prophylactic agent for prostate diseases. The dose of the active ingredient according to the present invention depends on the degree of absorption of the active ingredient in the body, the form of the preparation, the route of administration, the age of the subject to be treated, the kind of the specific disease or pathological condition to be treated, It may be appropriately selected according to the judgment of the prescriber, and the administration may be carried out once a day or divided into several times. Typical dosages are 0.001 mg / kg · day to 10 g / kg · day. Since the composition of the present invention has little toxicity and side effects, it can be safely used for prolonged use for preventive purposes.
The present invention also provides a health functional food composition for preventing and symptomatic improvement of prostate diseases, which comprises gum arabic extract as an active ingredient. The gum lucidum extract may be added to the health functional food of the present invention in an amount of preferably 0.01 to 100% by weight. The health functional food of the present invention includes forms such as tablets, capsules, pills, and liquids, and examples of foods to which the composition of the present invention can be added include various foods, beverages, gums, tea, vitamins , And health functional foods.
As described above, the composition of the present invention is excellent in inhibiting the expression of the androgen receptor and the prostate-specific antigen, and thus can be effectively used for prevention and treatment / symptom improvement of prostate diseases.
In addition, the composition of the present invention is a composition using a material that has been used for an alternative therapy for the treatment of diseases other than prostate diseases for a long period of time, and can be safely used without worrying about toxicity or side effects because the human body is secured. And is more effective for the treatment of prostate diseases.
FIG. 1 is an image of western blot showing the effect of gum arabicum extract on inhibition of PSA and AR expression in LNCap cells.
FIG. 2 is a graph showing that the gonad extract is effective to inhibit PSA expression in LNCap cells.
FIG. 3 is a graph showing that the extract of ganoderma lucidum exhibits an AR inhibitory effect in LNCap cells.
Hereinafter, the present invention will be described in more detail with reference to the following examples. However, these embodiments are merely examples for explaining the content and scope of the technical idea of the present invention, and thus the technical scope of the present invention is not limited or changed. It will be apparent to those skilled in the art that various changes and modifications can be made within the scope of the technical idea of the present invention based on these examples.
Example
Example 1: Preparation of gum arabicum extract
The gum extract was used in the Korean plant extract bank. The specific extraction method is as follows. 300 g of methanol was added to 20 g of dried gum stalks and subjected to low temperature extraction for 3 hours by sonication. Then, the obtained extract was filtered with a filter paper, and the filtration residue was extracted with 300 ml of methanol for 3 hours at low temperature, and the filtration was further repeated twice. When the extraction was completed, the filtrate was combined and concentrated under reduced pressure to obtain 1.14 g of the extract.
Example 2 Evaluation of PSA and AR Expression Inhibitory Effect of Gum Extract
The following experiment confirmed the effect of gum arabic extract on the expression of prostate-specific antigen and androgen receptor.
LNCaP cells (ATCC, USA), a male hormone-dependent human prostate cancer cell line, were plated in 6-well plates at a concentration of 1 × 10 6 cells / well and cultured at 37 ° C. for 15 hours. The cultured cells were treated with 1 μM Testosterone and 10, 100 or 200 μg / ㎖ of germinate extract and cultured for additional 72 hours. As a positive control (BPH), only 1μM of Testosterone was treated without ginger extract and 10μM of Finasteride, a treatment for benign prostatic hyperplasia, was treated with 1μM of Testosterone as a control (Fina). Treated group as a negative control (Control).
After incubation, the cells were treated with RIPA buffer (50 mM Tris-HCl, pH 8.0, with 150 mM sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate, with a protease inhibitor cocktail) And centrifuged at 12,000 rpm for 20 minutes to separate proteins. The separated proteins were quantified by BCA (Bicinchoninic acid) method.
Ten μg of the quantified protein was subjected to SDS-PEGE gel electrophoresis, and the protein was transferred to the PVDF membrane. Then, PVDF membrane was reacted with 5% skim milk for 1 hour to remove nonspecific binding proteins on the surface. The primary antibodies, AR, PSA and β-actin were diluted to 1: 2000, 1: 1000, and 1: 5000, respectively And reacted at 4 캜 for one day. The cells were treated with ECL kit (Amersham, UK) for 1 hour at room temperature and then incubated with anti-goat antibody (Anti-goat; 1: 5000, Santacruz, CA, USA, Anti-Rabbit, And the protein expression of AR and PSA was confirmed.
FIG. 1 is an electrophoresis image showing the result of Western blotting on PSA and AR protein, and FIGS. 2 and 3 are graphs showing the expression levels of PSA and AR protein in the control and experimental groups, respectively.
Figs. 1 to 3 show that the ginseng root extract inhibits the expression of PSA and AR by testosterone in a concentration-dependent manner. In particular, at the same treatment concentration, gum arabicum extract showed a remarkable effect of inhibiting PSA expression, and at a concentration of 100 μg / ml, the effect was remarkably greater than that of Finasteride, which is conventionally known as a therapeutic agent for prostate diseases. The inhibitory effect was similar to that of Finasteride.
Claims (4)
The ginseng extract is obtained by extracting leaves, stalks, bark or fruit by raw or drying, using one or a mixture of two or more selected from the group consisting of water and C1 to C4 lower alcohols as a solvent. A pharmaceutical composition for therapeutic use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150142201A KR101688018B1 (en) | 2015-10-12 | 2015-10-12 | Composition for Prevention or Treatment of Prostatic Diseases Comprising Celtis Choseniana Extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150142201A KR101688018B1 (en) | 2015-10-12 | 2015-10-12 | Composition for Prevention or Treatment of Prostatic Diseases Comprising Celtis Choseniana Extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101688018B1 true KR101688018B1 (en) | 2016-12-20 |
Family
ID=57734210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150142201A KR101688018B1 (en) | 2015-10-12 | 2015-10-12 | Composition for Prevention or Treatment of Prostatic Diseases Comprising Celtis Choseniana Extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101688018B1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190068080A (en) * | 2017-12-08 | 2019-06-18 | 성균관대학교산학협력단 | An anti-inflamatory composition comprising extract of Celtis choseniana as an active ingredient |
| KR20210132974A (en) | 2020-04-28 | 2021-11-05 | 충남대학교산학협력단 | Composition for Prophylaxis or Treatment of Prostatic Diseases or Hair Loss Comprising Scaphechinus mirabilis |
| KR20220160301A (en) | 2021-05-27 | 2022-12-06 | 충남대학교산학협력단 | Composition for Prevention or Treatment of Prostatic Desease Comprising Sargassum Horneri Extract |
| KR20230116192A (en) | 2022-01-28 | 2023-08-04 | 충남대학교산학협력단 | Composition for Prevention or Treatment of Prostatic Desease Comprising Artemisia fukudo Makino Extract |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10365A (en) | 1854-01-03 | James hamilton | ||
| US20130049929A1 (en) | 2010-01-14 | 2013-02-28 | Frank Gerlach | Diagnostic method and system for wireless door control systems |
| US20150074270A1 (en) | 2011-12-14 | 2015-03-12 | Seven Networks, Inc. | System and method for generating a report to a network operator by distributing aggregation of data |
-
2015
- 2015-10-12 KR KR1020150142201A patent/KR101688018B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10365A (en) | 1854-01-03 | James hamilton | ||
| US20130049929A1 (en) | 2010-01-14 | 2013-02-28 | Frank Gerlach | Diagnostic method and system for wireless door control systems |
| US20150074270A1 (en) | 2011-12-14 | 2015-03-12 | Seven Networks, Inc. | System and method for generating a report to a network operator by distributing aggregation of data |
Non-Patent Citations (1)
| Title |
|---|
| Bang Yeon Hwang. et al, `Cytotoxic triterpenes from the twigs of Celtis philippinensis', Phytochemistry, 2003, vol.62, 197-201* * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190068080A (en) * | 2017-12-08 | 2019-06-18 | 성균관대학교산학협력단 | An anti-inflamatory composition comprising extract of Celtis choseniana as an active ingredient |
| KR102015448B1 (en) | 2017-12-08 | 2019-08-28 | 성균관대학교산학협력단 | An anti-inflamatory composition comprising extract of Celtis choseniana as an active ingredient |
| KR20210132974A (en) | 2020-04-28 | 2021-11-05 | 충남대학교산학협력단 | Composition for Prophylaxis or Treatment of Prostatic Diseases or Hair Loss Comprising Scaphechinus mirabilis |
| KR20220160301A (en) | 2021-05-27 | 2022-12-06 | 충남대학교산학협력단 | Composition for Prevention or Treatment of Prostatic Desease Comprising Sargassum Horneri Extract |
| KR20230116192A (en) | 2022-01-28 | 2023-08-04 | 충남대학교산학협력단 | Composition for Prevention or Treatment of Prostatic Desease Comprising Artemisia fukudo Makino Extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101652073B1 (en) | Composition for Prevention or Treatment of Prostatic Diseases Comprising Stauntonia Hexaphylla Extract | |
| KR101688018B1 (en) | Composition for Prevention or Treatment of Prostatic Diseases Comprising Celtis Choseniana Extract | |
| JP2013155192A (en) | Processes for extracting phytochemicals from pomegranate solids and compositions and methods of use thereof | |
| US9017742B2 (en) | Using pomegranate extracts for increasing prostate specific antigen doubling time | |
| KR101733477B1 (en) | Composition for Prevention or Treatment of Prostatic Diseases Comprising Albizziae Cortex Extract | |
| CA2700338C (en) | Anti-aids, anti-tumor, immune system stimulating herbal composition and production method | |
| CN116568315A (en) | Composition for preventing and treating benign prostatic hyperplasia comprising extract of fruit of Ziziphus jujuba as effective component | |
| CN107198170A (en) | A kind of preparation formula of natural raspberry composite oral liquid | |
| Matsukawa et al. | Antiproliferative activity of root extract from gentian plant (Gentiana triflora) on cultured and implanted tumor cells | |
| US20050147701A1 (en) | Anti-prostate cancer composition and therapeutic uses therefor | |
| KR101706552B1 (en) | A stomach cancer treatment composition comprising extract of job's tears and preparation methods thereof | |
| KR102439723B1 (en) | Composition for Prophylaxis or Treatment of Prostatic Diseases or Hair Loss Comprising Scaphechinus mirabilis | |
| Yulianti et al. | Extract of bitter melon (Momordica Charantia L.) as a cytotoxic and anti proliferaton agent for cells WiDr (Colon Cancer) | |
| CA2721087A1 (en) | Anticancer methods using extracts of anemarrhena asphodeloides bunge | |
| Salim et al. | Phytochemical Screening and Therapeutic Effects of Binahong (Anredera cordifolia (Ten.) Steenis) Leaves | |
| KR102551879B1 (en) | Composition for Prevention or Treatment of Prostatic Desease Comprising Sargassum Horneri Extract | |
| KR102186292B1 (en) | A composition comprising mixture of the herb extract and sulfasalazine for preventing or treating colitis | |
| KR101746158B1 (en) | Composition for ameliorating atopic dermatitis comprising Gypsophila oldhamiana extract and use thereof | |
| KR20160109725A (en) | Novel use of Extract of Solani Nigri Herba | |
| KR100726006B1 (en) | Pharmaceutical composition comprising polysaccharides from Angelica gigas Nakai for inhibition of cancer metastasis | |
| CN106999531B (en) | Composition for lymphatic drainage | |
| KR20230116192A (en) | Composition for Prevention or Treatment of Prostatic Desease Comprising Artemisia fukudo Makino Extract | |
| KR20180119507A (en) | A composition comprising mixture of the herb extract and sulfasalazine for preventing or treating colitis | |
| KR102388984B1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING VACCINIUM BRACTEATUM Thunb. EXTRACT FOR Treating and Preventing Benign Prostate Hyperplasia | |
| KR101961789B1 (en) | Composite compositions for improvement benign prostatic hyperplasia comprising extracts of asparagus cochinchinensis, extracts of lycium chinense, extracts of cuscutae semen and extracts of torilis japonica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20191202 Year of fee payment: 4 |